181 related articles for article (PubMed ID: 37658083)
1. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.
Monjazeb AM; Daly ME; Luxardi G; Maverakis E; Merleev AA; Marusina AI; Borowsky A; Mirhadi A; Shiao SL; Beckett L; Chen S; Eastham D; Li T; Vick LV; McGee HM; Lara F; Garcia L; Morris LA; Canter RJ; Riess JW; Schalper KA; Murphy WJ; Kelly K
Nat Commun; 2023 Sep; 14(1):5332. PubMed ID: 37658083
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Chang JY; Lin SH; Dong W; Liao Z; Gandhi SJ; Gay CM; Zhang J; Chun SG; Elamin YY; Fossella FV; Blumenschein G; Cascone T; Le X; Pozadzides JV; Tsao A; Verma V; Welsh JW; Chen AB; Altan M; Mehran RJ; Vaporciyan AA; Swisher SG; Balter PA; Fujimoto J; Wistuba II; Feng L; Lee JJ; Heymach JV
Lancet; 2023 Sep; 402(10405):871-881. PubMed ID: 37478883
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D
BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
6. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
7. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R
JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal?
Gulstene S; Ruwanpura T; Palma D; Joseph N
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):733-740. PubMed ID: 36050221
[TBL] [Abstract][Full Text] [Related]
10. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
Doyen J; Poudenx M; Gal J; Otto J; Guerder C; Naghavi AO; Gérard A; Leysalle A; Cohen C; Padovani B; Ianessi A; Schiappa R; Chamorey E; Bondiau PY
Radiother Oncol; 2018 May; 127(2):239-245. PubMed ID: 29650404
[TBL] [Abstract][Full Text] [Related]
12. Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time?
Das M; Abdelmaksoud MH; Loo BW; Kothary N
Curr Treat Options Oncol; 2010 Jun; 11(1-2):24-35. PubMed ID: 20577833
[TBL] [Abstract][Full Text] [Related]
13. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.
Seo YS; Kim HJ; Wu HG; Choi SM; Park S
Thorac Cancer; 2019 Jun; 10(6):1489-1499. PubMed ID: 31124275
[TBL] [Abstract][Full Text] [Related]
14. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
Bilal H; Mahmood S; Rajashanker B; Shah R
Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
[TBL] [Abstract][Full Text] [Related]
15. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
17. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
[TBL] [Abstract][Full Text] [Related]
18. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
20. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]